Subscribe Become an Author Log In

Covering emerging technologies, innovations, and companies

Tim Sandle

Contributor Biopharma Insights

Dr. Sandle is the Head of Microbiology and Sterility Assurance at Bio Products Laboratory Limited (a pharmaceutical organization). Dr. Sandle is a chartered biologist (Royal Society for Biology) and holds a first class honors degree in Applied Biology; a Masters degree in education; and obtained his doctorate from Keele University.

Dr. Sandle has over twenty-five years experience of designing and operating a range of microbiological tests (including sterility testing, endotoxin LAL methodology, microbial enumeration, environmental monitoring, particle counting, bioburden, isolators, and water testing). In addition, Dr. Sandle is experienced in microbiological and quality batch review, microbiological investigation and policy development.

Dr. Sandle is an honorary tutor with the School of Pharmacy and Pharmaceutical Sciences, University of Manchester and is a lecturer for the university’s pharmaceutical microbiology MSc course. Dr. Sandle serves on several national and international committees relating to pharmaceutical microbiology and cleanroom contamination control (including the ISO cleanroom standards). He was chair of the Pharmig LAL action group and served on the Blood Service disinfection committee. He has written over five hundred book chapters, peer-reviewed papers, and technical articles relating to microbiology, healthcare, and pharmaceutical science; and delivered papers to over one hundred conferences.

Dr. Sandle is the editor of the Pharmaceutical Microbiology Interest Group Journal and runs an online microbiology website and forum ( Dr. Sandle is an experienced auditor and frequently acts as a consultant to the pharmaceutical and healthcare sectors.


Antibiotic resistance Antibiotics Artificial Intelligence Big Data Biopharma news Biotech Startup Digital Technologies Healthcare Infectious Diseases Market Research Microbiome Pharma 4.0 Pharmaceutical industry trends

Posts by this author

Big Investments for Human Microbiome Research

Big Investments for Human Microbiome Research

Major companies on the scene include Second Genome, Enterome, and EpiBiome. In addition, several new startups have entered the field. Amongst the most active investors, Global Engage reports, are Seventure Partners, Flagship Pioneering and BioGaia. In fact there are some 120 companies investing in analyzing data relating to the human microbiome. To take one example, companies such as uBiome are developing genomic tests meant to identify and diagnose harmful microbes in the body.

New Liposome Treatment for Community-acquired Pneumonia

New Liposome Treatment for Community-acquired Pneumonia

New research, published in The Lancet Infectious Diseases, presents the first clinical results with CAL02 in patients suffering from severe pneumonia, the first cause of infectious mortality in the world.

The findings are of significance for pharmaceutical companies and the medical sector. This is in the context of a time of great struggle for antibiotic companies given the increase in instances of antibiotic resistant bacteria. What is of particular global concern is the acceleration of resistance. U.S. Centers for Disease Control and Prevention (CDC) data finds that many high-income countries are entering a “post-antibiotic era.”

Genetic Test for Antimicrobial Resistance

Genetic Test for Antimicrobial Resistance

Scientists have put together a sensitive method to determine if bacteria carry a gene that can cause resistance to two common antibiotics. The test is rapid and has been tested against the bacterium which causes ‘strep throat’ and other respiratory illnesses.

Becoming Pharma 4.0: How Digital Transformation Is Reshaping Pharmaceuticals

Becoming Pharma 4.0: How Digital Transformation Is Reshaping Pharmaceuticals

The digital transformation of biopharmaceutical manufacturing is continuing at a rapid pace as companies attempt to mine the sources of data available. Innovations include predictive analytics, big data analytics, and creating the digital plant. Digital transformation offers a mechanism to revise its business model, to improve production processes, to design new drugs faster by using artificial intelligence to screen compounds and to increase responsiveness to customers. Furthermore, the volume of data processed by pharmaceutical firms shows no sign of slowing down. This means pharmaceutical companies must act quickly in terms of building core internal digital capabilities and moving beyond their traditional IT functions to all areas of the business.